Back to top

Analyst Blog

Simcere Pharmaceutical Group recently announced that it has entered into a strategic agreement with Bristol-Myers Squibb Company (BMY - Analyst Report).

The agreement further expands Simcere’s association with Bristol-Myers Squibb which goes back to 2010.

As per the agreement, both companies will collaborate on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb’s rheumatoid arthritis drug, Orencia.

Simcere will primarily focus on the development and regulatory activities which are mandatory to obtain market approval for Orencia SC in China. Both companies will share profits and losses related to Orencia SC in China.

Other financial terms of the agreement were not disclosed.

We remind investors that Simcere formed a strategic partnership with Bristol-Myers Squibb in Nov 2010 to co-develop candidate BMS-817378 in China while the latter retained rights of all other markets across the world.

Moreover, Simcere expanded its drug development partnership with Bristol-Myers Squibb in Dec 2011 to focus on the co-development of the latter’s cardiovascular disease candidate, BMS-795311.

Simcere already has drugs like Yingtaiqing and Iremod in its rheumatoid arthritis franchise. The addition of Orencia will further strengthen Simcere’s portfolio and should boost long-term growth.

We note that Orencia is approved for the treatment of rheumatoid arthritis in the US, Europe and Japan.  Orencia’s SC formulation was launched in the European markets in 2012.

We are encouraged by Simcere’s association with Bristol-Myers Squibb.

Simcere currently carries a Zacks Rank #3 (Hold). Right now, Actavis Inc. (ACT - Analyst Report) and Mylan Inc. (MYL - Analyst Report) look attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CTPARTNERS… CTP 13.33 +3.49%
SAIA INC SAIA 45.65 +1.00%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
FIRSTSERVIC… FSRV 55.66 -0.13%